Product Description
Mechanisms of Action: APM1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chroma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Myelodysplastic Syndrome|Acute Myeloid Leukemia|Leukemia
Phase 2: Non-Small-Cell Lung Cancer|Leukemia, Plasma Cell|Preleukemia|Acute Myeloid Leukemia|Multiple Myeloma|Pancreatic Cancer|Adenocarcinoma|Myelodysplastic Syndrome|Anemia, Refractory, with Excess of Blasts|Leukemia
Phase 1: Oncology Solid Tumor Unspecified|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Preleukemia|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12618001924246p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Surgical Wound Infection |
2020-05-04 |
|||
ACTRN12619001494123p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Pain Unspecified|Healthy Volunteers |
None |
|||
NCT01636609 |
NCI-2018-01817 | P1 |
Terminated |
Acute Myeloid Leukemia|Preleukemia|Myelodysplastic Syndrome |
2019-07-04 |
2020-04-14 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
NCT01638442 |
8265134 | P1 |
Completed |
Healthy Volunteers |
2012-07-01 |
2023-09-19 |
Primary Endpoints|Treatments|Trial Status |
|
NCT00737555 |
CHR-2797-003 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2008-03-01 |
2019-03-18 |
Treatments |
|
NCT00692354 |
CHR-2797-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2007-11-01 |
2019-03-18 |
Treatments |
|
2011-001914-33 |
MUK three | P2 |
Completed |
Multiple Myeloma |
2017-10-30 |
2022-03-13 |
Treatments |
|
NCT02452346 |
IST-CTI-MDS | P2 |
Completed |
Myelodysplastic Syndrome |
2017-10-25 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT02352831 |
NCT02352831 | P2 |
Terminated |
Adenocarcinoma|Pancreatic Cancer |
2017-10-20 |
2019-03-20 |
Treatments |
|
2012-000334-19 |
2012-000334-19 | P2 |
Active, not recruiting |
Acute Myeloid Leukemia |
2015-04-17 |
2022-03-13 |
Treatments |
|
NCT01567059 |
NCI-2012-00274 | P2 |
Completed |
Preleukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia |
2013-06-01 |
2022-04-06 |
Primary Endpoints|Treatments |
|
NCT01180426 |
The TOPAZ Study | P2 |
Unknown status |
Acute Myeloid Leukemia |
2013-06-01 |
2019-03-19 |
Treatments |
|
2009-014455-68 |
HOVON 103 AML Tosedostat | P2 |
Active, not recruiting |
Anemia, Refractory, with Excess of Blasts|Acute Myeloid Leukemia |
2013-02-16 |
2025-05-06 |
Treatments |
|
2008-006799-32 |
OPAL study | P2 |
Completed |
Acute Myeloid Leukemia |
2011-05-11 |
2022-03-13 |
Treatments |
|
NCT00780598 |
OPAL | P2 |
Completed |
Acute Myeloid Leukemia |
2011-03-01 |
2019-03-18 |
Treatments |
|
2005-004955-36 |
2005-004955-36 | P2 |
Completed |
Leukemia|Multiple Myeloma|Myelodysplastic Syndrome |
2008-07-14 |
2022-03-12 |
Treatments |
|
NCT00522938 |
CHR-2797-005 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2008-02-01 |
2019-03-21 |
Treatments |
|
NCT00689000 |
CHR-2797-002 | P2 |
Completed |
Myelodysplastic Syndrome|Preleukemia|Acute Myeloid Leukemia|Multiple Myeloma|Leukemia, Plasma Cell |
2007-12-01 |
2019-03-18 |
||
2011-000749-19 |
LI-1 | P3 |
Unknown status |
Acute Myeloid Leukemia|Myelodysplastic Syndrome |
2019-05-04 |
2025-06-23 |
Treatments |
|
ACTRN12612000848808 |
AMLM20 | P3 |
Terminated |
Myelodysplastic Syndrome|Leukemia |
2017-02-23 |
2024-08-29 |
Treatments |